nach oben

Erschienen in:

01.03.2015 | Original Paper

Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

verfasst von: Tianxiang Ge, Qiujin Shen, Ning Wang, Yurong Zhang, Zhouhong Ge, Wei Chu, Xiufang Lv, Fengbo Zhao, Weifeng Zhao, Jia Fan, Wenxin Qin

Erschienen in: Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The timely diagnosis and effective treatment are essential for improving the survival and prognosis of hepatocellular carcinoma (HCC) patients. Alpha-fetoprotein (AFP) is the most widely used biomarker for diagnosis of HCC, but the low sensitivity and specificity limits its clinical application. In this study, we evaluated the diagnostic capability of the combination of AFP with two novel potential biomarkers, dickkopf-1 (DKK1) and osteopontin (OPN), for HCC in 390 participants including 89 patients with HCC, 36 patients with liver cirrhosis, 65 patients with chronic hepatitis B, and 200 health controls. We found the combination of all three markers as a panel showed a better diagnostic performance than that of AFP alone, with increased AUC [0.948 (95 % CI 0.921–0.968) vs. 0.831 (95 % CI 0.790–0.867)] and sensitivity (88.76 vs. 71.91 %). Moreover, this combination showed a great improvement in diagnosing early-stage HCC patients. In conclusion, the combined use of AFP, DKK1, and OPN as a biomarker panel could enhance the diagnostic ability for HCC.

Nur mit Berechtigung zugänglich

Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13. doi:10.1634/theoncologist.2010-S4-05.CrossRefPubMed

Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–9. doi:10.3322/caac.21161.CrossRefPubMed

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38. doi:10.1016/j.jhep.2006.05.013.CrossRefPubMed

Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130(9):497–513. doi:10.1007/s00432-004-0572-9.CrossRefPubMed

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15):1437–47. doi:10.1056/NEJMoa0901282.PubMedCentralCrossRefPubMed

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. doi:10.1093/jnci/djn134.CrossRefPubMed

Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology (Baltimore, MD). 1990;12(6):1420–32.CrossRef

Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology (Baltimore, MD). 2005;42(5):1208–36. doi:10.1002/hep.20933.CrossRef

Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–31. doi:10.1056/NEJM198405313102204.CrossRefPubMed

10.

Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer. 1988;61(4):769–74.CrossRefPubMed

11.

Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23(10):1541–8. doi:10.1111/j.1440-1746.2008.05395.x.CrossRefPubMed

12.

Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8. doi:10.1053/j.gastro.2009.04.005.PubMedCentralCrossRefPubMed

13.

Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, et al. A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013;87(2):121–31. doi:10.1159/000346080.CrossRefPubMed

14.

Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357–62. doi:10.1038/34848.CrossRefPubMed

15.

Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al. Kremen proteins are dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002;417(6889):664–7. doi:10.1038/nature756.CrossRefPubMed

16.

Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50(5):948–57. doi:10.1016/j.jhep.2008.11.020.CrossRefPubMed

17.

Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26. doi:10.1016/S1470-2045(12)70233-4.CrossRefPubMed

18.

Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16(4):885–93.CrossRefPubMed

19.

Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39(4):410–33. doi:10.1053/j.seminoncol.2012.05.001.CrossRefPubMed

20.

Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci Off J Soc Toxicol. 2008;103(1):4–13. doi:10.1093/toxsci/kfm246.CrossRef

21.

Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (Baltimore, MD). 2012;55(2):483–90. doi:10.1002/hep.24703.CrossRef

22.

Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107(1):64–74. doi:10.1038/ajg.2011.312.PubMedCentralCrossRefPubMed

23.

Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. doi:10.1186/2046-4053-2-37.PubMedCentralCrossRefPubMed

24.

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology (Baltimore Md). 2009;50(3):661–2. doi:10.1002/hep.23190.CrossRef

25.

Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore Md). 2011;53(3):1020–2. doi:10.1002/hep.24199.CrossRef

26.

Block T, Mehta AS, London WT. Hepatocellular carcinoma of the liver. Cancer Biomark Sect A Dis Markers. 2010;9(1–6):375–83. doi:10.3233/CBM-2011-0165.

27.

Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57(11):1592–6. doi:10.1136/gut.2008.149062.CrossRefPubMed

28.

Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33(5):437–47. doi:10.1016/j.ctrv.2007.04.001.CrossRefPubMed

29.

Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67(6):2517–25. doi:10.1158/0008-5472.CAN-06-3369.CrossRefPubMed

30.

Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009;55(9):1656–64. doi:10.1373/clinchem.2009.125641.CrossRefPubMed

31.

Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int Off J Int Assoc Study Liver. 2011;31(10):1494–504. doi:10.1111/j.1478-3231.2011.02597.x.CrossRef

32.

Yang H, Chen GD, Fang F, Liu Z, Lau SH, Zhang JF, et al. Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma. Int J Biol Markers. 2013;28(3):286–97. doi:10.5301/jbm.5000015.CrossRef

33.

Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416–23. doi:10.1038/nm843.CrossRefPubMed

34.

Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010;103(6):861–9. doi:10.1038/sj.bjc.6605834.PubMedCentralCrossRefPubMed

35.

Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep. 2011;25(2):433–41. doi:10.3892/or.2010.1106.CrossRefPubMed

36.

Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Nat Compr Cancer Netw JNCCN. 2009;7(4):350–91.

37.

Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206–13.CrossRefPubMed

38.

Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037–44. doi:10.1111/j.1582-4934.2010.01115.x.PubMedCentralCrossRefPubMed

Titel: Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma
verfasst von: Tianxiang Ge
Qiujin Shen
Ning Wang
Yurong Zhang
Zhouhong Ge
Wei Chu
Xiufang Lv
Fengbo Zhao
Weifeng Zhao
Jia Fan
Wenxin Qin
Publikationsdatum: 01.03.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0367-z

Springer Medizin

Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer

Continuous, low-dose capecitabine for patients with recurrent colorectal cancer

The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma

Interaction of sonic hedgehog (SHH) pathway with cancer stem cell genes in gastric cancer

Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial

Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie